grepcent public filings, reorganized for comparison

Covista Inc. (CVSA)

CIK: 0000730464. SIC: 8200 Services-Educational Services. Latest 10-K as of: 2026-08-06.

SIC breadcrumb: Services > SIC Major Group 82 > SIC 8200 Services-Educational Services

SEC company page: https://www.sec.gov/edgar/browse/?CIK=730464. Latest filing source: 0001104659-26-092044.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2026 · period end 2026-06-30 · filed 2026-08-06 · accession 0001104659-26-092044 · source: SEC companyfacts

Revenue
1,954,085,000 USD verified
Net income
251,566,000 USD verified
Assets
3,012,708,000 USD verified
Free cash flow
392,726,000 USD computed
Net margin
12.87% computed
Operating margin
19.62% computed
Revenue YoY
+9.27% computed
ROE
17.40% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

CVSA ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 8200; per-ratio N printed.CVSA ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 8200; per-ratio N printed.RatioCVSAPeer medianPercentileNNet margin12.9%10.0%6011Operating margin19.6%13.7%7011Revenue growth9.3%7.1%7011FCF margin20.1%12.1%8011ROE17.4%16.4%6011ROA8.4%7.6%6011Liabilities / equity1.080.777011Current ratio1.091.753011

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 8200 Services-Educational Services, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue1,954,085,000USD20262026-08-06
Net income251,566,000USD20262026-08-06
Assets3,012,708,000USD20262026-08-06

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000730464.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric201420152017201820192020202120222023202420252026
Revenue1,207,909,000960,277,0001,013,843,000866,427,000899,248,0001,381,842,0001,450,826,0001,584,652,0001,788,290,0001,954,085,000
Net income122,283,00033,769,00095,168,000-85,334,00070,027,000310,991,00093,358,000136,777,000237,065,000251,566,000
Operating income181,268,000156,910,000155,830,000110,067,000110,399,00076,746,000168,170,000217,054,000341,542,000383,376,000
Diluted EPS1.910.541.60-1.581.366.432.053.396.187.04
Operating cash flow230,920,000239,189,000204,858,000107,692,000192,199,00010,601,000191,914,000295,775,000337,899,000470,422,000
Capital expenditures42,508,00046,622,00057,574,00039,605,00039,881,00031,054,00026,014,00048,893,00050,327,00077,696,000
Share buybacks48,508,000137,028,000252,852,000136,889,000100,000,000120,000,000123,133,000261,966,000213,125,000239,866,000
Assets2,315,018,0002,344,961,0002,242,696,0002,258,058,0003,084,843,0002,843,887,0002,810,541,0002,741,417,0002,752,352,0003,012,708,000
Liabilities639,694,000816,565,000841,623,000915,414,0001,781,983,0001,334,670,0001,353,205,0001,372,282,0001,318,727,0001,566,523,000
Stockholders' equity1,669,039,0001,519,286,0001,391,530,0001,309,750,0001,293,517,0001,491,386,0001,457,336,0001,369,135,0001,433,625,0001,446,185,000
Cash and cash equivalents240,426,000430,690,000204,202,000500,516,000476,377,000206,284,000260,826,000219,306,000199,601,000406,316,000
Free cash flow188,412,000192,567,000147,284,00068,087,000152,318,000-20,453,000165,900,000246,882,000287,572,000392,726,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric201420152017201820192020202120222023202420252026
Net margin10.12%3.52%9.39%-9.85%7.79%22.51%6.43%8.63%13.26%12.87%
Operating margin15.37%12.70%12.28%5.55%11.59%13.70%19.10%19.62%
Return on equity7.33%2.22%6.84%-6.52%5.41%20.85%6.41%9.99%16.54%17.40%
Return on assets5.28%1.44%4.24%-3.78%2.27%10.94%3.32%4.99%8.61%8.35%
Liabilities / equity0.380.540.600.701.380.890.931.000.921.08
Current ratio1.251.881.622.003.711.130.880.860.821.09

Industry Peer Context

Each number-line places CVSA against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

CVSA Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.CVSA Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.11 SIC peersMin -22.3%Median 10.0%Max 19.5%CVSA 12.9%

Operating margin peer context

CVSA Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.CVSA Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.11 SIC peersMin -34.6%Median 13.7%Max 25.3%CVSA 19.6%

ROE peer context

CVSA ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.CVSA ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.11 SIC peersMin -210.0%Median 16.4%Max 28.9%CVSA 17.4%

ROA peer context

CVSA ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.CVSA ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8200; peer count 11.11 SIC peersMin -52.4%Median 7.6%Max 21.8%CVSA 8.4%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

CVSA FY2026 free cash flow bridge from reported figures.CVSA FY2026 free cash flow bridge from reported figures.CVSA free cash flow bridgeFY2026: operating cash flow less capital expendituresSource: SEC companyfacts FY2026.Free cash flow bridgeReported amount$0.0B$250.0M$500.0M$470.4MOperating cash flow-$77.7MCapex$392.7MFree cash flow

Figure provenance: SEC companyfacts FY 2026. Operating cash flow: accession 0001104659-26-092044; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001104659-26-092044; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001104659-26-092044; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

CVSA revenue, last 5 periods. Source: SEC companyfacts FY2026.CVSA revenue, last 5 periods. Source: SEC companyfacts FY2026.CVSA RevenueLatest point: FY2026 = $2.0BSource: SEC companyfacts FY2026.Fiscal yearReported revenue$0.0B$1.0B$2.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: Revenues. Source concepts: us-gaap:Revenues.

CVSA net income, last 5 periods. Source: SEC companyfacts FY2026.CVSA net income, last 5 periods. Source: SEC companyfacts FY2026.CVSA Net incomeLatest point: FY2026 = $251.6MSource: SEC companyfacts FY2026.Fiscal yearNet income$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

CVSA operating income, last 5 periods. Source: SEC companyfacts FY2026.CVSA operating income, last 5 periods. Source: SEC companyfacts FY2026.CVSA Operating incomeLatest point: FY2026 = $383.4MSource: SEC companyfacts FY2026.Fiscal yearOperating income$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

CVSA diluted eps, last 5 periods. Source: SEC companyfacts FY2026.CVSA diluted eps, last 5 periods. Source: SEC companyfacts FY2026.CVSA Diluted EPSLatest point: FY2026 = $7.04/shareSource: SEC companyfacts FY2026.Fiscal yearDiluted EPS (USD/share)$0.00/share$4.00/share$8.00/shareFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

CVSA operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.CVSA operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.CVSA Operating cash flowLatest point: FY2026 = $470.4MSource: SEC companyfacts FY2026.Fiscal yearOperating cash flow$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

CVSA capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.CVSA capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.CVSA Capital expendituresLatest point: FY2026 = $77.7MSource: SEC companyfacts FY2026.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

CVSA share buybacks, last 5 periods. Source: SEC companyfacts FY2026.CVSA share buybacks, last 5 periods. Source: SEC companyfacts FY2026.CVSA Share buybacksLatest point: FY2026 = $239.9MSource: SEC companyfacts FY2026.Fiscal yearShare buybacks$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

CVSA assets, last 5 periods. Source: SEC companyfacts FY2026.CVSA assets, last 5 periods. Source: SEC companyfacts FY2026.CVSA AssetsLatest point: FY2026 = $3.0BSource: SEC companyfacts FY2026.Fiscal yearAssets$0.0B$2.0B$4.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: Assets. Source concepts: us-gaap:Assets.

CVSA liabilities, last 5 periods. Source: SEC companyfacts FY2026.CVSA liabilities, last 5 periods. Source: SEC companyfacts FY2026.CVSA LiabilitiesLatest point: FY2026 = $1.6BSource: SEC companyfacts FY2026.Fiscal yearLiabilities$0.0B$1.0B$2.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

CVSA stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.CVSA stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.CVSA Stockholders' equityLatest point: FY2026 = $1.4BSource: SEC companyfacts FY2026.Fiscal yearStockholders' equity$0.0B$1.0B$2.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

CVSA cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.CVSA cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.CVSA Cash and cash equivalentsLatest point: FY2026 = $406.3MSource: SEC companyfacts FY2026.Fiscal yearCash and cash equivalents$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

CVSA free cash flow, last 5 periods. Source: SEC companyfacts FY2026.CVSA free cash flow, last 5 periods. Source: SEC companyfacts FY2026.CVSA Free cash flowLatest point: FY2026 = $392.7MSource: SEC companyfacts FY2026.Fiscal yearFree cash flow-$250.0M$0.0B$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

22 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000730464.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2023-Q12022-09-300.05reported discrete quarter
2023-Q22022-12-310.52reported discrete quarter
2023-Q32023-03-311.00reported discrete quarter
2024-Q12023-09-30368,845,00010,646,0000.25reported discrete quarter
2024-Q22023-12-31393,242,00039,891,0000.98reported discrete quarter
2024-Q32024-03-31412,658,00036,821,0000.93reported discrete quarter
2024-Q42024-06-30409,907,00049,419,000derived Q4 = FY annual - nine-month YTD
2025-Q12024-09-30417,400,00046,165,0001.18reported discrete quarter
2025-Q22024-12-31447,729,00075,856,0001.98reported discrete quarter
2025-Q32025-03-31466,055,00060,832,0001.59reported discrete quarter
2025-Q42025-06-30457,106,00054,212,000derived Q4 = FY annual - nine-month YTD
2026-Q12025-09-30462,288,00061,832,0001.67reported discrete quarter
2026-Q22025-12-31503,385,00076,376,0002.11reported discrete quarter
2026-Q32026-03-31487,030,00041,637,0001.20reported discrete quarter
2026-Q42026-06-30501,382,00071,721,000derived Q4 = FY annual - nine-month YTD

Quarterly Charts

CVSA quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.CVSA quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.CVSA Quarterly RevenueLatest point: 2026-Q4 = $501.4MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Revenue$0.0B$375.0M$750.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: Revenues. Source concepts: us-gaap:Revenues.

CVSA quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.CVSA quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.CVSA Quarterly Net incomeLatest point: 2026-Q4 = $71.7MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Net income$0.0B$125.0M$250.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001104659-26-092044; filed 2026-08-06. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

CVSA quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.CVSA quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.CVSA Quarterly Diluted EPSLatest point: 2026-Q3 = $1.20/shareSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Diluted EPS (USD/share)$0.00/share$2.00/share$4.00/share2023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q22026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001104659-26-057163; filed 2026-05-07. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read CVSA's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read CVSA's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001104659-26-057163.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-05-07. Report date: 2026-03-31.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report. It should also be read in conjunction with our consolidated financial statements and the related Management’s Discussion and Analysis of Financial Condition and Results of Operation as contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K), the Cautionary Disclosure Regarding Forward-Looking Statements, the Risk Factors included in the 2025 Form 10-K, and the Financial Aid and Legislative and Regulatory Requirements disclosures set forth in this report. Covista reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2026 is for our third quarter of fiscal year 2026.

Throughout this MD&A, we sometimes use information derived from the Consolidated Financial Statements and the notes thereto but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain of these items are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. See the “Non-GAAP Financial Measures and Reconciliations” section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures.

Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands. Discussions throughout this MD&A are based on continuing operations unless otherwise noted.

Available Information

We use our website (www.covista.com) as a routine channel of distribution of company information, including press releases, presentations, and supplemental information, as one means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, you should monitor our website in addition to following press releases, SEC filings, and public conference calls and webcasts. You can receive notifications of new information posted on our investor relations website in real time by signing up for email alerts. You may also access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, as well as other reports relating to us that are filed with or furnished to the SEC, free of charge in the investor relations section of our website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The content of the websites mentioned above is not incorporated into and should not be considered a part of this report.

26

Table of Contents

Segments

We present three reportable segments as follows:

Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.

Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.

Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.

“Home Office” includes activities not allocated to a reportable segment. Financial and descriptive information about Covista’s reportable segments is presented in Note 18 “Segment Information” to the Consolidated Financial Statements.

Third Quarter Highlights

Financial and operational highlights for the third quarter of fiscal year 2026 include:

Column 1Column 2Column 3
Covista revenue increased 4.5%, or $21.0 million, to $487.0 million in the third quarter of fiscal year 2026 compared to the prior year period driven by increased revenue across all of our segments. Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026.
Column 1Column 2Column 3
Net income decreased 31.6%, or $19.2 million, to $41.6 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The net income decrease was also driven by a loss from discontinued operations and increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives, partially offset by a reduction in asset impairments.
Column 1Column 2Column 3
Diluted earnings per share decreased 24.5%, or $0.39, to $1.20 in the third quarter of fiscal year 2026 compared to the prior year period driven by the decrease in net income, partially offset by lower diluted shares due to share repurchases.
Column 1Column 2Column 3
Adjusted net income decreased 5.8%, or $4.2 million, to $69.0 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted net income decrease was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Column 1Column 2Column 3
Adjusted earnings per share increased 3.1%, or $0.06, to $1.98 in the third quarter of fiscal year 2026 compared to the prior year period driven by lower diluted shares due to share repurchases, partially offset by the decrease in adjusted net income.
Column 1Column 2Column 3
For the January 2026 and March 2026 sessions, total student enrollment at Chamberlain decreased 0.7% and increased 0.5%, respectively, compared to the same sessions last year.
Column 1Column 2Column 3
As of March 31, 2026, total student enrollment at Walden increased 12.3% compared to March 31, 2025.

27

Table of Contents

Column 1Column 2Column 3
For the January 2026 semester, total student enrollment at the medical and veterinary schools increased 4.1% compared to the same semester last year.
Column 1Column 2Column 3
On March 2, 2026, we entered into Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement (the “Term Loan B Amendment”) to incur new term loans under Term Loan B in an aggregate principal amount of $510.0 million with a maturity date of March 2, 2033. In addition, on March 2, 2026, we repaid the previously outstanding $103.3 million principal amount of Term Loan B and the remaining $405.0 million outstanding principal amount of the Senior Secured Notes due 2028. See Note 13 “Debt” to the Consolidated Financial Statements for additional information.
Column 1Column 2Column 3
Covista repurchased a total of 637,538 shares of its common stock under its share repurchase programs at an average cost of $103.04 per share during the third quarter of fiscal year 2026. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors.

Results of Operations

Revenue

The following tables present revenue by segment detailing the changes from the prior year periods (in thousands):

Three Months Ended March 31, 2026
ChamberlainWalden (1)Medical and VeterinaryConsolidated (1)
Fiscal year 2025$192,592$178,418$95,045$466,055
Growth4,3718,1578,44720,975
Fiscal year 2026$196,963$186,575$103,492$487,030
% change from prior year2.3%4.6%8.9%4.5%

Nine Months Ended March 31, 2026
ChamberlainWaldenMedical and VeterinaryConsolidated
Fiscal year 2025$541,508$511,237$278,439$1,331,184
Growth18,48882,86020,171121,519
Fiscal year 2026$559,996$594,097$298,610$1,452,703
% change from prior year3.4%16.2%7.2%9.1%
Column 1Column 2
(1)Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden segment revenue would have increased 14.7%, or $26.2 million, to $204.6 million and consolidated revenue would have increased 8.4%, or $39.0 million, to $505.0 million.

Chamberlain

Chamberlain Student Enrollment:

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001104659-26-092044. The complete FY 2026 MD&A is published at /company/CVSA/mda/fy2026/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-08-06. Report date: 2026-06-30.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report. It should also be read in conjunction with the Cautionary Disclosure Regarding Forward-Looking Statements (see the Introduction section preceding Part I), the Risk Factors (see Item 1A. “Risk Factors”), and the Financial Aid and Legislative and Regulatory Requirements (see Item 1. “Business”) disclosures set forth in this report. Covista reports on a fiscal year period ending on June 30.

Throughout this MD&A, we sometimes use information derived from the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” and the notes thereto but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain of these items are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. See the “Non-GAAP Financial Measures and Reconciliations”

35

Table of Contents

section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures.

Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands. Discussions throughout this MD&A are based on continuing operations unless otherwise noted.

The following discussion is on the comparison between fiscal year 2026 and fiscal year 2025 results. For a discussion on the comparison between fiscal year 2025 and fiscal year 2024 results, see the MD&A included in Covista’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, as filed with the SEC.

Segments

We present three reportable segments as follows:

Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.

Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.

Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offer degree and certificate programs in the medical and veterinary postsecondary education industry.

“Home Office” includes activities not allocated to a reportable segment. Financial and descriptive information about Covista’s reportable segments is presented in Note 19 “Segment Information” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data.”

Fiscal Year 2026 Highlights

Financial and operational highlights for fiscal year 2026 include:

Column 1Column 2Column 3
Covista revenue increased 9.3%, or $165.8 million, to $1,954.1 million in fiscal year 2026 compared to the prior year driven by increased revenue across all segments.
Column 1Column 2Column 3
Net income increased 6.1%, or $14.5 million, to $251.6 million in fiscal year 2026 compared to the prior year. This increase was primarily driven by an increase in revenue along with decreases in interest expense and asset impairments, partially offset by a loss from discontinued operations and increases in strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, and the provision for income taxes.
Column 1Column 2Column 3
Diluted earnings per share increased 13.9%, or $0.86, to $7.04 in fiscal year 2026 compared to the prior year driven by the increase in net income and lower diluted shares due to share repurchases.
Column 1Column 2Column 3
Adjusted net income increased 15.3%, or $39.1 million, to $294.7 million in fiscal year 2026 compared to the prior year. This increase was primarily driven by an increase in revenue and a decrease in interest expense, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, and the provision for income taxes.
Column 1Column 2Column 3
Diluted adjusted earnings per share increased 23.7%, or $1.58, to $8.25 in fiscal year 2026 compared to the prior year driven by the increase in adjusted net income and lower diluted shares due to share repurchases.
Column 1Column 2Column 3
For fiscal year 2026, average total student enrollment at Chamberlain increased 1.1% compared to the prior year. For the May 2026 session, total student enrollment at Chamberlain increased 1.6% compared to the same session last year.

36

Table of Contents

Column 1Column 2Column 3
For fiscal year 2026, average total student enrollment at Walden increased 13.2% compared to the prior year. As of June 30, 2026, total student enrollment at Walden increased 14.0% compared to June 30, 2025.
Column 1Column 2Column 3
For fiscal year 2026, average total student enrollment at the medical and veterinary schools increased 4.5% compared to the prior year. For the May 2026 semester, total student enrollment at the medical and veterinary schools increased 7.3% compared to the same semester last year.
Column 1Column 2Column 3
On August 6, 2025, we entered into Amendment No. 4 to Credit Agreement and Incremental Assumption Agreement (the “Revolver Amendment”), to (i) increase available commitments under our revolving facility by $100.0 million (resulting in aggregate outstanding commitments of $500.0 million under the revolving facility after giving effect to the Revolver Amendment), (ii) extend the maturity and commitment termination date of our revolving facility to August 6, 2030, and (iii) reduce the pricing on any drawn revolving loans to the Secured Overnight Financing Rate (“SOFR”) plus an applicable margin ranging from 2.25% to 3.00% or an alternate base rate (“ABR”) plus an applicable margin ranging from 1.25% to 2.00% depending on Covista’s net first lien leverage ratio for such period.
Column 1Column 2Column 3
On March 2, 2026, we entered into Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement (the “Term Loan B Amendment”) to incur new term loans under Term Loan B in an aggregate principal amount of $510.0 million with a maturity date of March 2, 2033. In addition, on March 2, 2026, we repaid the previously outstanding $103.3 million principal amount of Term Loan B and the remaining $405.0 million outstanding principal amount of the Senior Secured Notes due 2028. See Note 13 “Debt” to the Consolidated Financial Statements in Item 8. “Financial Statements and Supplementary Data” for additional information.
Column 1Column 2Column 3
Covista repurchased a total of 2,421,920 shares of its common stock under its share repurchase programs at an average cost of $98.35 per share during fiscal year 2026. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors.

Results of Operations

Revenue

The following table presents revenue by segment detailing the changes from the prior year (in thousands):

Year Ended June 30, 2026
ChamberlainWaldenMedical and VeterinaryConsolidated
Fiscal year 2025$725,774$693,430$369,086$1,788,290
Growth24,438111,50329,854165,795
Fiscal year 2026$750,212$804,933$398,940$1,954,085
% change from prior year3.4%16.1%8.1%9.3%

Chamberlain

Chamberlain Student Enrollment:

Fiscal Year 2026
SessionJuly 2025Sept. 2025Nov. 2025Jan. 2026Mar. 2026May 2026
Total students37,69739,84639,27840,14540,76739,501
% change from prior year4.5%2.2%(1.0)%(0.7)%0.5%1.6%
Fiscal Year 2025
SessionJuly 2024Sept. 2024Nov. 2024Jan. 2025Mar. 2025May 2025
Total students36,06138,98739,69140,44540,56438,891
% change from prior year12.1%11.7%11.5%8.7%6.8%5.8%

Chamberlain revenue increased 3.4%, or $24.4 million, to $750.2 million in fiscal year 2026 compared to the prior year driven by higher tuition rates and enrollment. Enrollment increased in pre-licensure nursing programs in all fiscal year 2026 sessions; however, enrollment has declined in post-licensure nursing programs during fiscal year 2026. Chamberlain

37

Table of Contents

is achieving pre-licensure growth by optimizing investments in student enrollment and experience while leveraging scale through a national footprint with in-person and online curriculum delivery modalities. Management is focused on optimizing marketing and enrollment operations to address post-licensure enrollment.

Tuition Rates:

Current tuition rates in fiscal year 2026 increased compared to the prior fiscal year for the Bachelor of Science in Nursing (“BSN”) onsite and online degree, Master of Science in Nursing (“MSN”), Master of Social Work (“MSW”) and Master of Public Health (“MPH”) online degree programs. The average increase across all of these programs was approximately 3.4% from the prior year.

Walden

Walden Student Enrollment:

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for CVSA

Indicators mapped to this company's SIC classification (industry 8200 Services-Educational Services) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/CVSA.md · JSON record: /company/CVSA.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt